biostudies-literatureUnknown12(34)Fu YAxitinib is a potent vascular endothelial growth factor receptor (VEGFR) inhibitor, which has a strong inhibitory effect on the three isoforms of VEGFR 1-3. Having strong therapeutic efficacy, its broad use is limited by its side effects such as hypertension, proteinuria, cardiovascular damage, and liver and kidney dysfunction. Selenium compounds are broadly reported to have a good protective effect on cardiovascular disease, inflammation, infection, and immune function. In this study, a selenium substitute of axitinib was synthesized, and its anti-renal cell carcinoma activity and side effects were investigated. The results of the study indicated that Se-axitinib had potent antitumor activity on renal cell carcinoma (RCC), alleviated vascular hyperpermeability, and also alleviated axitiniRSC advances21821-21826https://www.ebi.ac.uk/biostudies/studies/S-EPMC9358677biostudies-literatureSelenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity.PMC9358677Rong YZhao CYu PAhmad Ridwan KFu YTeng YSaxu RZheng WKong XfalseSelenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity.Axitinib is a potent vascular endothelial growth factor receptor (VEGFR) inhibitor, which has a strong inhibitory effect on the three isoforms of VEGFR 1-3. Having strong therapeutic efficacy, its broad use is limited by its side effects such as hypertension, proteinuria, cardiovascular damage, and liver and kidney dysfunction. Selenium compounds are broadly reported to have a good protective effect on cardiovascular disease, inflammation, infection, and immune function. In this study, a selenium substitute of axitinib was synthesized, and its anti-renal cell carcinoma activity and side effects were investigated. The results of the study indicated that Se-axitinib had potent antitumor activity on renal cell carcinoma (RCC), alleviated vascular hyperpermeability, and also alleviated axitini2022-01-01T00:00:00Z2022 Aug2025-04-05T08:56:24.088Z2025-04-05T08:56:24.088ZS-EPMC93586773604308010.1039/d2ra01882a